Ceva producing aMPV experimental autogenous vaccine using US-origin isolate
Ceva Animal Health has started antigen production for an experimental autogenous vaccine to fight the emerging avian metapneumovirus (aMPV) disease.
Ceva Animal Health has started antigen production for an experimental autogenous vaccine to fight the emerging avian metapneumovirus (aMPV) disease.
Light and dark cycles within a 24-hour period play a crucial role in maintaining physiological and behavioral rhythms in animals.
Avian metapneumovirus (aMPV) has swept through production facilities across the US since its initial appearance in late 2023. aMPV infections can result in mass morbidity, significant egg drops and, in the most severe cases, mortalities.
[random-sponsor]
Copyright ©Feeks Media LLC, 2024 | All rights reserved
info@modernpoultry.media
privacy policy | site map